Healthcare: 3 Tough Luck Tumbles – Are They Buys?

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 15 August 2018

⏱️ 25 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Spark Therapeutics, Rite Aid, and Alnylam shares have tumbled following news, but that doesn’t necessarily make all three stocks worth buying. Stocks: ONCE, RAD, ALNY

Transcript

Click on a timestamp to play from that location

0:00.0	This episode of Industry Focus is brought to you by Sinios Health, a new fully integrated
0:04.6	bio-pharmaceutical Solutions Organization that's the result of a merger between Inc. research and
0:09.7	Inventive Health. Sinios Health is focused on a simple end goal, shortening the distance from
0:14.9	lab to life.
0:16.4	To learn more, visit sinios health.com. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.
0:27.0	Today is August 15th and we'll be talking health care.
0:29.0	I'm your host Christine Harjus and I'm joined by fool dot com contributor Todd Campbell via Skype.
0:34.4	We have a ton to cover today an update on Rite Aid's Woes, a historic FDA approval, and first,
0:40.8	Spark Therapeutics, ticker ONCE once,
0:44.5	lost 28% of its market cap on Tuesday of last week.
0:49.5	We weren't able to cover it on our last health care show,
0:52.0	so we're digging in today. Todd what
0:53.8	happened? It's funny I was looking at these three stocks or we're following and
0:58.3	it's like the three tough luck tumbles. Yeah it's it's pretty much all bad news today, so buckle up.
1:04.0	Yeah, so, you know, investors, bear with us, bear with us.
1:07.0	We're going to try and we'll hold your hands and get you through this crazy time.
1:11.0	Yeah, I guess history does rhyme, right, Christine?
1:13.0	I mean, Spark therapeutics reported data for its hemophilia A gene therapy and like you said, it got whacked after the data got parsed by investors.
1:25.6	That's very similar to what we saw happen back in December, right?
1:29.3	When they reported interim data for the same exact gene therapy and investors concluded after looking at that data that
1:38.6	Spark Therapeutics SPK8001 may not be as robust of a treatment option as competitor biomerans, which
1:51.0	biomeran is working on a similar gene therapy.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.